# Dare Bioscience (DARE) — Earnings

DARE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/dare/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.20 |
| EPS estimate | −$0.30 |
| EPS surprise | +32.59% |
| Revenue surprise | +11150.51% |
| Revenue | $187,546.00 |
| Revenue estimate | $1,667.00 |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1401914/000140191426000043/dare-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/2d09cd61-6975-c44f-9e48-ec500f6d9faf.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | −$0.30 | −$0.20 | 32.59% | $1,667.00 | $187,546.00 |
| Q1 2026 | May 14, 2026 | −$0.31 | −$0.20 | 34.43% | $27,000.00 | $152,455.00 |
| Q4 2025 | Mar 26, 2026 | −$0.44 | $0.03 | 106.82% | $751,500.00 | $1.0M |
| Q3 2025 | Nov 13, 2025 | −$0.38 | −$0.28 | 27.08% | $13,067.00 | $2,262.00 |
| Q2 2025 | Aug 14, 2025 | −$0.58 | −$0.45 | 22.45% | $282,750.00 | — |
| Q1 2025 | May 13, 2025 | −$0.58 | −$0.50 | 13.79% | $600,000.00 | $25,427.00 |
| Q3 2024 | Nov 14, 2024 | −$0.69 | −$0.55 | 19.71% | $1.0M | $41,691.00 |
| Q2 2024 | Aug 12, 2024 | −$0.04 | $1.52 | 3997.44% | $7.9M | $22,438.00 |
| Q1 2024 | May 14, 2024 | −$0.72 | −$0.84 | -16.67% | $260,500.00 | $9,302.00 |
| Q4 2023 | Mar 28, 2024 | −$1.08 | −$0.84 | 22.22% | $2.4M | $1.8M |
| Q3 2023 | Nov 9, 2023 | −$1.18 | −$1.09 | 6.99% | $733,333.00 | $1.0M |
| Q2 2023 | Aug 10, 2023 | −$1.18 | −$1.20 | -1.69% | $1.1M | — |
| Q1 2023 | May 11, 2023 | −$1.20 | −$1.08 | 10.00% | $1.7M | — |
| Q4 2022 | Mar 30, 2023 | −$1.64 | −$2.28 | -39.02% | — | — |
| Q3 2022 | Nov 10, 2022 | −$1.40 | −$0.96 | 31.43% | $8.0M | — |
| Q2 2022 | Aug 9, 2022 | −$0.76 | $0.00 | 100.00% | $10.0M | $10.0M |
| Q1 2022 | May 12, 2022 | −$1.71 | −$1.20 | 29.82% | $362,750.00 | — |
| Q4 2021 | Mar 31, 2022 | −$1.75 | −$1.32 | 24.66% | $1.7M | — |
| Q3 2021 | Nov 10, 2021 | −$1.53 | −$2.16 | -41.18% | $5.7M | — |
| Q2 2021 | Aug 12, 2021 | −$1.89 | −$2.16 | -14.29% | — | — |

## Frequently Asked Questions

### When did Dare Bioscience (DARE) last report earnings?

Dare Bioscience last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did DARE beat earnings estimates?

Yes. Dare Bioscience reported EPS of −$0.20 for Q2 2026 against a −$0.30 estimate — a 32.59% beat.

### How much revenue did DARE report last quarter?

Dare Bioscience reported $187,546.00 in revenue for Q2 2026, against a consensus estimate of $1,667.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).